Examining the effect of three low-intensity pediatric obesity interventions: a pilot randomized controlled trial

Shannon M Looney1, Hollie A Raynor2

  • 1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA University of Tennessee, Knoxville, TN, USA shannon.looney@cchmc.org.

Clinical Pediatrics
|July 10, 2014
PubMed

Insights

Low-intensity pediatric obesity treatments can effectively reduce standardized body mass index (z-BMI) and sugar-sweetened beverage intake. These interventions show promise for feasibility in primary care settings.

Area of Science:

  • Pediatric Health
  • Obesity Treatment
  • Primary Care Interventions

Background:

  • Primary care settings are well-suited for addressing pediatric obesity.
  • There is a need for effective, low-intensity interventions (≤25 contact hours over 6 months) to reduce standardized body mass index (z-BMI).
  • Interventions should be deliverable by primary care providers.

Purpose of the Study:

  • To investigate the impact of three distinct low-intensity pediatric obesity treatments on z-BMI.
  • To evaluate interventions delivered within a 6-month timeframe and with limited contact hours (≤25).

Main Methods:

  • A pilot randomized controlled trial involving 22 families with children (mean age 8.0 ± 1.8 years, mean z-BMI 2.34 ± 0.48).
  • Participants were randomized into three 6-month conditions: newsletter only (N), newsletter plus growth monitoring (N + GM), or newsletter plus growth monitoring and family-based behavioral counseling (N + GM + BC).
  • Measurements included anthropometrics, child eating behaviors, and leisure-time behaviors.

Main Results:

  • A significant main effect of time was observed for both z-BMI and daily servings of sugar-sweetened beverages (P < .05).
  • Both z-BMI and sugar-sweetened beverage consumption decreased over the study period.
  • Improvements were noted across all intervention groups, suggesting a general positive effect of the implemented strategies.

Conclusions:

  • Low-intensity obesity treatments are capable of reducing z-BMI in pediatric populations.
  • These interventions demonstrate potential feasibility for implementation within primary care settings.
  • Further research is warranted to optimize and scale these approaches.
Abstract

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
364
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
405
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
324
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
437
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
400